Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27593612 | 1.00 | LMNA (0.37) | LMNASLC6A4KDM5CKDM4CGAA | |
| SCHEMBL3843654 | 0.95 | OPRD1 (0.35) | LMNASLC6A4KDM5CKDM4CGAA | |
| SCHEMBL13617949 | 0.84 | OPRD1 (0.35) | SLC6A4OPRD1SLC6A2SLC6A3MEN1 | |
| SCHEMBL6334699 | 0.78 | CPB2 (0.56) | LMNAGAACPB2 | |
| SCHEMBL6324387 | 0.78 | CPB2 (0.56) | LMNAGAACPB2 | |
| SCHEMBL6324378 | 0.78 | CPB2 (0.56) | LMNAGAACPB2 | |
| SCHEMBL8366278 | 0.76 | CPB2 (0.49) | CPB2 | |
| SCHEMBL3085221 | 0.76 | ALDH1A1 (0.52) | GAAKMT2AALDH1A1 | |
| SCHEMBL31690313 | 0.75 | HSD17B10 (0.51) | GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL20095093 | 0.75 | NPSR1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
| CN-1443173-A | Substituted imidazoles as TAFI a inhibitors | PFIZER LTD (US) | 2003-09-17 | — | — | CN | disclosed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147229-A1 | Pharmaceuticals | BDKRB1, TFPI, BDKRB2 | LMNA 895/4885SLC6A4 3535/4885KDM5C 2575/4885 |
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | LMNA 907/4885SLC6A4 3537/4885KDM5C 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.